Australian-based reproductive biotechnology company Memphasys (ASX:MEM) has enhanced its business development and sales capabilities following the appointment of Dr David Ali as its Director of Business Development.

The company describes Dr Ali as a ‘highly credentialed’ senior executive with over 40 years’ experience in medical management, business development, sales, and marketing for pharmaceutical, medical device, and diagnostic companies in animal and human reproduction.

Dr Ali has gathered this experience through positions held within prestigious organisations, including the Commonwealth Scientific and industrial Research Organisation (CSIRO), Bayer (ETR:BAYN), AstraZeneca (LON:AZN), Novo Nordisk (CPH:NOVO-B), and Biogen (NASDAQ:BIIB).

“Dr David Ali is a highly credentialed and experienced executive who will add great value to Memphasys”

The company also notes Dr Ali’s key role will be to build key relationships with distributors, key opinion leaders/clinical end users, supply chain managers, regulatory bodies, and government authorities across all target markets and to lead the sales and marketing function.

In addition, it is reported the new Director of Business Development will also assess potential markets and develop sales and marketing plans for the most advanced products under development, including ROSA, Memphasys’ proprietary Rapid Oxidative Stress Assay. Dr Ali will also work closely with the University of Newcastle team led by Memphasys’ Research Director Professor John Aitken.

Addressing the appointment of Dr David Ali, Memphasys Chief Executive Officer (CEO) and Managing Director Alison Coutts said: “Dr David Ali is a highly credentialed and experienced executive who will add great value to Memphasys. His appointment is timely as we are now at the point where we can focus more intensely on business development, marketing and sales, especially for the Felix(™) device.”

Memphasys reports the appointment of Dr Ali is key to bringing to fruition the marketing and sales of its products to international markets and in the short term, the Felix(™) device in early markets, such as Japan, Canada and New Zealand.

Other targeted markets include higher regulatory markets such as India, Australia, China, US and Europe, with hopes of increasing the focus on these latter markets once the approval for Felix(™) device sales are received from relevant regulatory bodies.

Memphasys is an ASX-listed reproductive biotechnology company specialising in developing and commercialising novel medical devices, diagnostics, and media for application to human and animal reproduction.